It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Spalt-like proteins are Zinc finger transcription factors from Caenorhabditis elegans to vertebrates, with critical roles in development. In vertebrates, four paralogues have been identified (SALL1-4), and SALL2 is the family’s most dissimilar member. SALL2 is required during brain and eye development. It is downregulated in cancer and acts as a tumor suppressor, promoting cell cycle arrest and cell death. Despite its critical functions, information about SALL2 regulation is scarce. Public data indicate that SALL2 is ubiquitinated and phosphorylated in several residues along the protein, but the mechanisms, biological consequences, and enzymes responsible for these modifications remain unknown. Bioinformatic analyses identified several putative phosphorylation sites for Casein Kinase II (CK2) located within a highly conserved C-terminal PEST degradation motif of SALL2. CK2 is a serine/threonine kinase that promotes cell proliferation and survival and is often hyperactivated in cancer. We demonstrated that CK2 phosphorylates SALL2 residues S763, T778, S802, and S806 and promotes SALL2 degradation by the proteasome. Accordingly, pharmacological inhibition of CK2 with Silmitasertib (CX-4945) restored endogenous SALL2 protein levels in SALL2-deficient breast MDA-MB-231, lung H1299, and colon SW480 cancer cells. Silmitasertib induced a methuosis-like phenotype and cell death in SW480 cells. However, the phenotype was significantly attenuated in CRISPr/Cas9-mediated SALL2 knockout SW480 cells. Similarly, Sall2-deficient tumor organoids were more resistant to Silmitasertib-induced cell death, confirming that SALL2 sensitizes cancer cells to CK2 inhibition. We identified a novel CK2-dependent mechanism for SALL2 regulation and provided new insights into the interplay between these two proteins and their role in cell survival and proliferation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); University of California-San Francisco, Dept of Orofacial Sciences and Dept of Anatomy, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 University of Western Ontario, Department of Biochemistry, Schulich School of Medicine & Dentistry, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884)
3 University of Western Ontario, Department of Biochemistry, Schulich School of Medicine & Dentistry, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884); Odyssey Therapeutics, Boston, USA (GRID:grid.39381.30)
4 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663)
5 Universidad de Concepción, Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663)
6 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Inmunovirología. Departamento de Microbiologia. Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663)
7 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad Católica de la Santísima Concepción, Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Concepción, Chile (GRID:grid.412876.e) (ISNI:0000 0001 2199 9982)
8 German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg. Cancer Progression and Metastasis Group, Heidelberg, Germany (GRID:grid.482664.a); Heidelberg University, Faculty of Biosciences, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373)